NL-OMON45980已完成不适用
A randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic, and pharmacodynamic study of MET409 after single and multiple ascending oral dose administration in healthy male subjects - MET409 SAD and MAD study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Healthy male subjects
- •-18-65 years, inclusive, at screening
- •-BMI 18.0-30.0 kg/m2, inclusive, at screening
- •-Weight >=60 kg
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial with blinded patients and personnel investigating the safety and preliminary dose-finding effects of the medicinal product LL-37 in hard-to-heal leg ulcers in comparison with an inactive substance (placebo)EUCTR2012-002100-41-SEipopeptide AB35
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate severity, using an implanted catheter and a SynchroMed® II pump.Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III)EUCTR2007-007853-30-SEeuroNova AB
撤回
不适用
A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 with bupivacaine interaction study administered intrathecally in healthy volunteers.pain after surgeryPost operative pain10007867NL-OMON35341Xenome Ltd.44
已完成
不适用
A randomized, double-blind, placebo-controlled, serial-cohort, single ascending dose of Xen2174 PK/PD study administered intrathecally in healthy volunteers.10007867pain after surgeryPost operative painNL-OMON35658Xenome Ltd.32
招募中
不适用
A double-blind, randomized, placebo-controlled, sequential ascending single-dose study to evaluate the pharmacokinetic and tolerability profiles of teriflunomide in healthy Korean subjectsDiseases of the nervous systemKCT0000539Sanofi-Aventis Korea36